25 pharmaceutical and biological companies accrued impairment of goodwill last year

25 pharmaceutical and biological companies accrued impairment of goodwill last year

25 pharmaceutical and biological companies accrued impairment of goodwill last year
On April 20, Sauna and Yewang made statistics based on the data of Flush Flush. Of the 130 listed medical and biological companies that have released the 2019 annual report, 25 of them have accrued goodwill, and 7 of them1ppm, the highest and largest in Shanghai medicine, up to 7.US $ 0.5 billion, Jin Dawei, China Resources Sanjiu, Anke Biology and others followed.25 companies accrued impairment of goodwill and 3 net revenues of both revenues decreased. Among the 25 companies accrued for impairment of goodwill, 3 companies accounted for both revenues and net profits.Branch Biology and Xinlitai.Reporting the average, Leadman’s revenue was more than twice.33%, with a net profit lower than 84 in ten years.41% is the company with the largest expansion in revenue and net profit, of which 764 is a goodwill impairment provision.07,000 yuan.Leadman said that the reasons for the reported decline in performance include actively responding to the changes in the biochemical diagnostic reagent industry and the increasingly fierce market competition environment. The company adjusted its marketing channels and marketing policies; some subsidiaries did not meet expectations, and obviousMention the goodwill impairment provision, etc.Leadman ‘s goodwill was born in 2014, when the company purchased 25% of Desai Diagnostics (Shanghai) Co., Ltd. and 31% of Desai Diagnostics (Shanghai) Co., Ltd. by issuing shares and paying cash.In 2019, 100% equity of Shanghai Shangtuo Industrial Co., Ltd. was purchased by cash payment, and the difference between the price paid at the time of the merger and the fair value of the identifiable net assets of the acquired subsidiary (acquired portion).Jindawei accrued a large amount of goodwill impairment due to the unsatisfactory performance of its subsidiary VitaBest Nutrition (hereinafter referred to as “VB”), and the subsidiary had accrued 2376 goodwill impairment losses in 2018.540,000 US dollars.In 2019, Jindawei’s net profit was 4.$ 5.1 billion, 34 in the previous decade.425%, mainly due to the impairment of the above goodwill and the decline in the gross profit margin of vitamin products.VB is Jindawei September 1, 2015.An enterprise acquired by USD 01 billion.In 2019, market competition intensified, VB orders were inadequate, and gross profit fell, replacing the achievement of the 2019 annual performance target.In the first quarter of 2020, VB sales revenue expanded with the same period of the previous year as expected, which was far below the expected target.In addition, VB’s second largest customer lowered its forecasted purchase volume in 2020, and Jindawei accrued goodwill impairment losses2.74ppm and intangible assets-customer relationship impairment loss 4216.250,000 yuan.Shanghai Pharmaceuticals has accrued a goodwill impairment of more than 700 million, and its assets have decreased by nearly 10%. Among the 130 companies that publish annual reports, Shanghai Pharmaceuticals has the highest revenue, reaching 1865.At 6.6 billion U.S. dollars, its impairment of goodwill is also the highest, at 7.05 billion.Among them, Vitaco, Gansu Tiansen and Big Global separately provided goodwill impairment provision5.6.8 billion yuan, 3947.01 million yuan and 9725.710,000 yuan, which also led to the impairment of Shanghai Pharmaceutical Assets.8%.Vitaco is Shanghai Pharmaceuticals 2016 with 9.A US $ 3.8 billion merger and acquisition of nutrition companies, the main markets are Australia and New Zealand, products include health products, sports nutrition and health food.In 2019, the scale of Vitaco’s business failed to meet expectations. Shanghai Pharmaceuticals said that the overall performance of the Chinese business is still a certain gap from the acquisition and expectations.Due to the above-mentioned registration and filing system for offline sales of imported health products, and the time-consuming reorganization of the procedure, Vitaco imported health products can only be traded through cross-border e-commerce and purchasing methods, so the development is slow.In 2018, Shanghai Pharmaceutical Xinyi Pharmaceutical Factory, a wholly-owned subsidiary of Shanghai Pharmaceuticals, contributed capital1.8.9 billion yuan to acquire 51% equity of Gansu Tiansen.Gansu Tiansen is an API manufacturer with chymotrypsin API-Miyuan as its main business. Chymotrypsin is a classic medicine that can be replaced by nebulization healing and effective for expectorant and anti-inflammatory.In 2019, although the revenue scale of the Tiansen chymotrypsin product line in Gansu has improved, the market for chymotrypsin preparations has been squeezed to a certain extent through the launch of a large number of new atomized extraction preparations.Big Global is a company that has completed 100% equity acquisitions in Shanghai Pharmaceuticals from 2013 to 2019. Big Global is a wholly-owned subsidiary of Shanghai Pharmaceutical Dongying (Jiangsu) Pharmaceuticals.The forthcoming provision for the impairment of goodwill against Big Global, Shanghai Pharmaceuticals said that although currently only four domestic companies are allowed to produce the drug, the generic anesthetic drugs are under the centralized control of the state, and the scope of sales terminal customers is limited, covering the leading products.The agglomeration effect leads to lower profitability than expected.Editor Yue Qingxiu proofreading Li Shihui